Claro Advisors’s abrdn Life Sciences Investors HQL Stock Holding History

Claro Advisors’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,533	Closed	-$208K	–	222
2020 Q4	$208K	Buy	+10,533	New	+$195K	0.11%	197
2019 Q1	–	Sell	-4,823	Closed	-$98K	–	499
2018 Q4	$98K	Buy	+4,823	New	+$84.9K	0.08%	232

Other funds holding HQL

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return

Matisse Capital Portland, Oregon $234M AUM 19.72% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Cohen & Steers New York $57.6B AUM 8.03% 1-Year Est. Return

1CP

1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return

Claro Advisors's HQL Position: Q1 2021 in Review

Claro Advisors sold out of abrdn Life Sciences Investors (HQL) in Q1 2021, closing a stake of 10,533 shares — an estimated $208K sold.

Claro Advisors first reported a position in HQL in Q4 2018 and held it in 2 quarters. The position peaked at $208K in Q4 2020. 65 funds tracked by Wall St. Rank hold HQL as of Q1 2021.

Claro Advisors reported no remaining abrdn Life Sciences Investors position as of Q1 2021 after selling out during the quarter.
Claro Advisors sold 10,533 abrdn Life Sciences Investors shares in Q1 2021, an estimated $208K.
Claro Advisors first reported a position in abrdn Life Sciences Investors in Q4 2018 and held it in 2 quarters.
Claro Advisors's abrdn Life Sciences Investors position peaked at $208K in Q4 2020.
65 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2021.

Based on Claro Advisors's 13F filing for Q1 2021, filed 17 May 2021.